1. WHWK's CEO and CSO will participate in H.C. Wainwright's series. 2. The event takes place on June 26, 2025, at 10 AM ET. 3. WHWK's ADC portfolio aims to improve cancer treatment efficacy. 4. Their therapies target difficult-to-treat cancers using advanced technologies. 5. WHWK's assets are licensed from WuXi Biologics for global commercialization.
The participation of top executives in a major event can raise investor confidence, reminiscent of past instances where similar engagements for biotech companies led to price appreciation ahead of product launches.
The announcement of a high-profile event with key leadership suggests robust confidence in company direction, increasing potential near-term interest from both investors and analysts.
Immediate investor interest may spike as the event date approaches, particularly if positive discussions about product advancements and clinical results are showcased.
PRNewswire -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that Dave Lennon, PhD, President and CEO, and David Dornan, PhD, Chief Scientific Officer, will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, June 26, 2025, at 10 AM ET.
To register in advance, please use this link. A live webcast of the event can be accessed by visiting the "Investors & News" page on the Whitehawk Therapeutics website and will be available for replay for approximately 30 days following the event.
Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Contact: contact@whitehawktx.com